UNSPSC 51386401: Balsalazide

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P80AL8J7ZP. European Medicines Agency schedules Balsalazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06092MIG. Balsalazide generally arises in the molecular formula C17H15N3O6.

UNSPSC 51386401 Balsalazide is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent state and local solicitations tagged to this code show little direct purchasing activity for balsalazide itself. Instead, the code's recent opportunities reflect broader pharmaceutical and health-product procurement — naloxone and drug deactivation systems for community health initiatives, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and exploratory direct-to-manufacturer prescription programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities). The mix reflects both direct single-jurisdiction buys and cooperative-purchasing vehicles that aggregate demand across multiple states and participating localities.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, on a fixed-fee basis with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, signaling intent to bypass traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with awards effective July 1, 2026, and evaluation weighted heavily on price competitiveness (75 percent). All three solicitations require FDA compliance, comprehensive insurance coverage, and E-Verify or equivalent employment verification.